Foresee Pharmaceuticals

Focus: Foresee Pharmaceuticals is a publicly traded drug delivery technology company headquartered in Newark, Delaware, focusing on neurology and respiratory/oncology indications. The company operates a diversified pipeline spanning Phase 1 through Phase 3 development across multiple therapeutic areas.

Neurology

Profile data last refreshed Yesterday · AI intelligence enriched 2w ago

Funding Stage

PUBLIC

Open Jobs

About Foresee Pharmaceuticals

AI assessmentNot Hiring

No open roles listed right now. Follow Foresee Pharmaceuticals to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthStrong

Pipeline

Late-stage

6 Phase 3+

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

Hyperpolarized 129Xe

Emphysema

N/A

Clinical Trials (1)

NCT04761393Characterizing Matrix Metalloproteinase-12 (MMP12) in Sputum

N/A

Help build intelligence for Foresee Pharmaceuticals

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Portfolio spans 16 active trials with 7 Phase 3 programs, offering multiple near-term clinical catalysts and advancement opportunities across oncology, respiratory, and rare disease
Established drug delivery technology platform enables differentiated approaches to marketed and developmental compounds including Leuprolide and Triptorelin formulations
Public company status provides equity upside potential and established infrastructure, with focus on high-value indications (prostate cancer, pulmonary hypertension, asthma/COPD)

Watch Out For

Currently zero active job openings signals potential organizational freeze, belt-tightening, or completion of recent hiring cycle—limited near-term career movement
Missing financial data (revenue, R&D spend, cash position) raises transparency concerns and prevents assessment of runway, burn rate, and funding stability

Generated by Claude from Foresee Pharmaceuticals's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

FP-025

Healthy

Phase 1

Clinical Trials (1)

NCT03304964A Phase 1, Pharmacokinetics of the MMP-12 Inhibitor FP-025 After Multiple Oral Ascending Doses in Healthy Subjects

Phase 1

FP-020

Healthy

Phase 1

Clinical Trials (1)

NCT06334211Safety, Tolerability, and Pharmacokinetics, of Single and Multiple Ascending Doses of FP-020 in Healthy Adult Volunteers

Phase 1